Santen
As of the edition of 20 October 2026, Santen runs 6 drugs, 6 of them marketed; it is on route A at 0 targets and on route B at 7 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 6 |
| Total | 6 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Cyclosporine | none listed | 3 |
| Timolol | none listed | 5 |
| Atropine | none listed | 12 |
| Latanoprost | none listed | 5 |
| Netarsudil | Ends 2034 (patent) | 6 |
| Tafluprost | none listed | 2 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 7 targets.
All 7 rows on route A or B
In the product7 company-target rows on route A or B; 4 are not shown here, and no score is.
See all 7 targets where Santen needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Eye: 4 trials led